[Role of etiol (amifostine) in the treatment of patients with malignant lymphoma].
The material is devoted to using of amifostinum as cytoprotor during polychemotherapy application in patients with malignant lymphomas. 10 patients (5 with lymphogranulomatosis, 4 with non-Hodgkin's lymphoma and 1 with Ewing's sarcoma) were receiving along with cytostatic therapy amifostinum. The patients treated with combined therapy had less side effects of polychemotherapy than a control group which had been receiving only polychemotherapy. The number of lymphocytes was constant in the group using amifostinum in contrast to another group where decrease of lymphocytes by 24% was noted. Owing to amifostinum we could complete the course of treatment even in patients whose state didn't allow us of sufficiently using polychemotherapy.
Sivkovich
S A
SA
Pavlenko
Iu V
IuV
Gnat
N V
NV
D000293:Adolescent; D000328:Adult; D004999:Amifostine / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001772:Blood Cell Count; D003131:Combined Modality Therapy; D006801:Humans; D008223:Lymphoma / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D020011:Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D020011:Protective Agents; D004999:Amifostine